Vanguard Group
RVMD icon

Vanguard Group’s Revolution Medicines RVMD Stock Holding History

Vanguard Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.33B Buy
16,719,886
+1,056,792
+7% +$69.3M 0.02% 604
2025
Q3 		$731M Sell
15,663,094
-98,597
-0.6% -$3.86M 0.01% 847
2025
Q2 		$580M Sell
15,761,691
-850,344
-5% -$32.7M 0.01% 945
2025
Q1 		$587M Sell
16,612,035
-484,420
-3% -$19.7M 0.01% 901
2024
Q4 		$748M Buy
17,096,455
+2,185,082
+15% +$110M 0.01% 815
2024
Q3 		$676M Buy
14,911,373
+533,076
+4% +$23.2M 0.01% 863
2024
Q2 		$558M Sell
14,378,297
-378,815
-3% -$14.2M 0.01% 921
2024
Q1 		$476M Buy
14,757,112
+122,721
+0.8% +$3.64M 0.01% 1024
2023
Q4 		$420M Buy
14,634,391
+4,990,800
+52% +$120M 0.01% 1073
2023
Q3 		$267M Buy
9,643,591
+303,088
+3% +$8.99M 0.01% 1282
2023
Q2 		$250M Buy
9,340,503
+37,950
+0.4% +$931K 0.01% 1344
2023
Q1 		$201M Buy
9,302,553
+1,740,643
+23% +$42.9M 0.01% 1453
2022
Q4 		$180M Buy
7,561,910
+577,908
+8% +$12.3M ﹤0.01% 1487
2022
Q3 		$138M Buy
6,984,002
+1,416,990
+25% +$31.1M ﹤0.01% 1609
2022
Q2 		$109M Sell
5,567,012
-490,919
-8% -$9.56M ﹤0.01% 1768
2022
Q1 		$155M Sell
6,057,931
-241,678
-4% -$5.26M ﹤0.01% 1710
2021
Q4 		$159M Buy
6,299,609
+59,411
+1% +$1.67M ﹤0.01% 1731
2021
Q3 		$172M Buy
6,240,198
+971,634
+18% +$28.3M ﹤0.01% 1693
2021
Q2 		$167M Buy
5,268,564
+418,302
+9% +$14.6M ﹤0.01% 1729
2021
Q1 		$223M Buy
4,850,262
+812,442
+20% +$36.4M 0.01% 1527
2020
Q4 		$160M Buy
4,037,820
+587,719
+17% +$23.2M ﹤0.01% 1592
2020
Q3 		$120M Buy
3,450,101
+2,131,334
+162% +$59M ﹤0.01% 1594
2020
Q2 		$41.6M Buy
1,318,767
+229,117
+21% +$7.2M ﹤0.01% 2092
2020
Q1 		$23.9M Buy
+1,089,650
New +$30.2M ﹤0.01% 2201

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group's RVMD Position: Q4 2025 in Review

Vanguard Group increased its Revolution Medicines (RVMD) stake by 6.7% in Q4 2025, buying an estimated $69.3M and bringing the position to 16,719,886 shares worth $1.33B. The position accounts for 0.02% of the portfolio, ranked #604.

Vanguard Group first reported a position in RVMD in Q1 2020 and has held it in 24 quarters since. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Vanguard Group held 16,719,886 shares of Revolution Medicines worth $1.33B as of Q4 2025.
  • Vanguard Group bought 1,056,792 Revolution Medicines shares in Q4 2025, an estimated $69.3M.
  • Revolution Medicines made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #604 holding.
  • Vanguard Group first reported a position in Revolution Medicines in Q1 2020 and has held it in 24 quarters since.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.